Mesoblast Investor Presentation — June 2020

Document content

ASX: MSB ; Nasdaq: MESO Global Leader in Allogeneic Cellular

Medicines for Inflammatory Diseases

Financial Year Ended June 30, 2020CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation includes forward-looking statements thatrelate tofuture events orourfuture financial performance andinvolve known andunknown risks, uncertainties andother factors thatmay cause ouractual results,

levels ofactivity, performance orachievements todiffer materially from anyfuture results, levels ofactivity, performance orachievements expressed orimplied bythese forward-looking statements .Wemake such forward -

looking statements pursuant tothesafe harbor provisions ofthePrivate Securities Litigation Reform Actof1995 andother federal securities laws.Allstatements other than statements ofhistorical facts contained inthis

presentation areforward-looking statements .Words such as,butnotlimited to,“believe, ”“expect, ”“anticipate, ”“estimate, ”“intend, ”“plan, ”“targets, ”“likely, ”“will,”“would, ”“could, ”andsimilar expressions orphrases identify

forward -looking statements .Wehave based these forward -looking statements largely onourcurrent expectations andfuture events ,recent changes inregulatory laws, andfinancial trends thatwebelieve may affect our

financial condition, results ofoperation, business strategy andfinancial needs .These statements may relate to,butarenotlimited to:expectations regarding thesafety orefficacy of,orpotential applications for,Mesoblast's

adult stem celltechnologies ;expectations regarding thestrength ofMesoblast's intellectual property, thetimeline forMesoblast's regulatory approval process, andthescalability andefficiency ofmanufacturing processes ;

expectations about Mesoblast's ability togrow itsbusiness andstatements regarding itsrelationships with current andpotential future business partners andfuture benefits ofthose relationships ;statements concerning